American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

AVAI BIO, INC. (AVAI)

$0.17 -8.81% OTC: AVAI · 15-min delayed

LAS VEGAS, Nevada
Public · OTC: AVAI

Visit website Follow

$276.3KRevenue · FY2023

-$1.1MNet income

AVAIOTC

About AVAI BIO, INC.

AVAI BIO INC

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · OTC: AVAI
Headquarters: LAS VEGAS, Nevada
Industry: Software
Website: Visit site

Registry IDs

Ticker: AVAI OTC
SEC CIK: 1740797
EIN: 384053064
SIC: 7374 Services-Computer Processing & Data Preparation

Embed this company’s badge

Show Avai BIO, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/avai-bio-inc/"><img src="https://americancompanies.com/badge/avai-bio-inc.svg" alt="Avai BIO, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow AVAI BIO, INC. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2023: $276.3K
Net income: -$1.1M
Total assets: $224.7K

Source: SEC EDGAR · updated Jun 7, 2026

OTC: AVAI

$0.17 -8.81%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.12 $0.78

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

Avai BIO, Inc. (AVAI) Stock Price

Reported a net loss of $1.1M in FY2023.
Trading 78% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review AVAI BIO, INC..

Write a review

Newsroom

News about AVAI BIO, INC.

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Benzinga · 2026-05-20 · positive Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy Benzinga · 2026-05-20 · positive Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference Benzinga · 2026-04-07 · positive The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step Benzinga · 2026-04-01 · positive Scalable Biotech Manufacturing Unlocks a $14B Market Benzinga · 2026-03-27 · positive Anti-Aging Protein Research Takes a Step Forward with Cell Cloning Benzinga · 2026-03-24 · positive

News & sentiment via Polygon.io

FAQ

Avai BIO, Inc.: frequently asked questions

Is Avai BIO, Inc. an American company?

Avai BIO, Inc. is a US-based company headquartered in Las Vegas, Nevada, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Avai BIO, Inc. headquartered?

Avai BIO, Inc. is headquartered in Las Vegas, Nevada, United States.

Is Avai BIO, Inc. publicly traded?

Yes — Avai BIO, Inc. is a publicly traded company. Its stock trades under the ticker symbol AVAI on the OTC.

What does Avai BIO, Inc. do?

Avai BIO, Inc. is an American Software company in the Technology & Electronics sector.

Explore